Clinical trials: Ophthalmic Disorders
Dry Eye Syndromes
Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the dose-response of OPC-12759 suspension in dry eye patients
- Trial name
- NCT00475319
- Testing
- 1% OPC-12759 ophthalmic suspension, 2% OPC-12759 ophthalmic suspension
- Where
- 6 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Myopia
Study of ACUVUE® ADVANCE® PLUS Contact Lenses.
The purpose of this study is to compare ACUVUE® ADVANCE® Plus contact lenses made prior to process qualification (prePQ) against the ACUVUE® ADVANCE® Plus lenses made after the process qualification (postPQ).
- Trial name
- NCT01244893
- Testing
- Acuvue Advance Plus prePQ, Acuvue Advance Plus postPQ
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Myopia, Astigmatism
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
The purpose of this study is to evaluate differences in the comfort at the end of the month between Air Optix® lenses versus Biofinity® lenses in habitual daily wear symptomatic soft contact lens wearers.
- Trial name
- NCT01629693
- Testing
- Lotrafilcon B contact lenses, Comfilcon A contact lenses
- Volunteers
- 398 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease
This study will evaluate the safety and efficacy of a carboxymethylcellulose based eye drop formulation compared with carboxymethylcellulose based preservative-free lubricant eye drops (OPTIVE™) in subjects with dry eye disease.
- Trial name
- NCT01664949
- Testing
- Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
- Where
- 12 sites in Australia, Belgium and 6 more
- Volunteers
- 460 people
- Sponsor
- Allergan
Ametropia
Clinical Characterization of Symptomatic Populations
This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of symptomatic and asymptomatic subject populations.
- Trial name
- NCT03319212
- Testing
- senofilcon A contact lenses
- Where
- 2 sites in United States, Canada
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Presbyopia
CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers
The purpose of this study is to evaluate CLEAR CARE® PLUS (CCP) compared to non-HYDRAGLYDE® multi-purpose contact lens solutions in presbyopes currently wearing soft contact lenses and experiencing symptoms of dryness.
- Trial name
- NCT02965833
- Testing
- 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix, Habitual Multi-Purpose Contact Lens Solution, Habitual Contact Lenses
- Volunteers
- 126 people
- Sponsor
- Alcon, a Novartis Company
Dry Eye Disease
Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who…
- Trial name
- NCT00827255
- Testing
- Cyclosporine Ophthalmic Emulsion 0.05%
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Allergan
Myopia
Fitting Evaluation of Hydrogel and Silicone Hydrogel Sphere Design Contact Lenses
The aim of this non-dispensing fitting study is to evaluate the short term lens fit, vision performance of three monthly replacement sphere lenses.
- Trial name
- NCT03098745
- Testing
- Omafilcon A, Somofilcon A, Omafilcon A - Proclear (PC)
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CooperVision, Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Myopia
BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study
Two week, Open Label, randomized, bilateral, crossover, 1 week of daily wear in each combination (lens / disinfecting cleaning system).
- Trial name
- NCT02537730
- Testing
- Bioclean MPS VII, Aosept Clearcare, comfilcon A
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- CooperVision, Inc.
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Infections, Eye Infections
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers
- Trial name
- NCT00575367
- Testing
- AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ocular Hypertension, Glaucoma
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma.
- Trial name
- NCT01033422
- Testing
- CF101
- Where
- 3 sites in Bulgaria, Israel
- Volunteers
- 89 people
- Sponsor
- Can-Fite BioPharma
Cataract
DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
A comparison of the ability of DisCoVisc to that of other ophthalmic viscosurgical devices (OVDs) (DuoVisc, Healon5 or Amvisc PLUS) regarding endothelial protection and anterior chamber space maintenance during non-eventful…
- Trial name
- NCT00712244
- Testing
- DisCoVisc, DuoVisc, Healon5
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Alcon Research
Myopia
Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP)
The purpose of this study is to evaluate the lens fit (mechanical and cosmetic lens fit) of the printed etafilcon A with polyvinylpyrrolidone (PVP).
- Trial name
- NCT01180777
- Testing
- etafilcon A (A), etafilcon A (B), etafilcon A (C)
- Where
- 6 sites in United States
- Volunteers
- 95 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.